Severe infections
Conditions
Brief summary
The number of days under treatment with broad-spectrum antibiotics in the group receiving the MODIFY strategy compared to patients treated by standard of care.
Detailed description
Time to first change of antibiotics, Time to the first sterile blood culture, Maintenance of the same antimicrobial(s) in case of activity against the pathogen, At least 2-point decrease of baseline SOFA score by day 7, 28-day mortality, 90-day mortality, Incidence of laboratory documented Clostrioides difficile infection, Length of hospital stay, Cost of hospitalization, Time to escalation of antibiotics, Time to de-escalation of antibiotics
Interventions
DRUGTAZOBACTAM
DRUGPIPERACILLIN
DRUGMICAFUNGIN
DRUGRELEBACTAM
DRUGVABORBACTAM
DRUGLINEZOLID
DRUGVANCOMYCIN
DRUGCEFTRIAXONE
DRUGTEICOPLANIN
DRUGIMIPENEM
DRUGANIDULAFUNGIN
DRUGCEFTAZIDIME
DRUGAVIBACTAM
DRUGMEROPENEM
DRUGCEFUROXIME
DRUGCEFTOLOZANE
Sponsors
Hellenic Institute For The Study Of Sepsis
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of days under treatment with broad-spectrum antibiotics in the group receiving the MODIFY strategy compared to patients treated by standard of care. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first change of antibiotics, Time to the first sterile blood culture, Maintenance of the same antimicrobial(s) in case of activity against the pathogen, At least 2-point decrease of baseline SOFA score by day 7, 28-day mortality, 90-day mortality, Incidence of laboratory documented Clostrioides difficile infection, Length of hospital stay, Cost of hospitalization, Time to escalation of antibiotics, Time to de-escalation of antibiotics | — |
Countries
Greece
Outcome results
None listed